e6vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September 2008
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
|
Oncolytics
Biotech Inc.
(Registrant) |
| |
| |
|
|
|
|
| |
| Date: September 22, 2008 |
|
By: |
|
/s/ Brad Thompson
Brad Thompson
President and CEO |
 |
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Collaborators to Present REOLYSIN® Clinical Trial
Results and Preclinical Research at Upcoming Conferences
CALGARY,
AB, — September 22, 2008 — Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today
announced the participation of five of its collaborators and their schedule of presentations at
four conferences through November 15, 2008 covering clinical trial results and preclinical research
on REOLYSIN®.
“It’s an important time for Oncolytics as we begin to share additional results of our ongoing
clinical trial and preclinical research programs for REOLYSIN®,” said Dr. Brad
Thompson, President and CEO of Oncolytics. “It is the results of these trials that should help us
to determine the late-stage clinical path forward for REOLYSIN®.”
Dr. Kevin Harrington and colleagues are scheduled to present a poster presentation entitled “Phase
I Trial of Oncolytic Reovirus (Reolysin) in Combination with Carboplatin/Paclitaxel in Patients
with Advanced Solid Cancers” at the International Society for Biological Therapy of Cancer (iSBTc)
annual meeting, being held in San Diego, California from October 31-November 2, 2008.
Prof. Hardev Pandha and colleagues are scheduled to present a poster presentation entitled “A Phase
I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration
of a Wild-Type Reovirus (REOLYSIN®) in Combination with Docetaxel to Patients with
Advanced Malignancies” at the iSBTc annual meeting.
Dr. Monica Mita et al is scheduled to make two oral presentations, both entitled “A Phase II Study
of Intravenous Reolysin (Wild Type Reovirus) in the Treatment of Patients with Bone and Soft Tissue
Sarcomas Metastatic to the Lung” at the Chemotherapy Foundation Symposium XXVI, being held in New
York from November 4-8, 2008 and also at the Connective Tissue Oncology Society (CTOS) meeting,
being held in London, U.K. from November 13-15, 2008.
Dr. Anders Kolb and colleagues are scheduled to deliver a poster presentation entitled “Systemic
Administration of Reolysin Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination
with Cisplatin and Radiation” at the CTOS meeting.
Prof. Hardev Pandha and colleagues are scheduled to deliver a poster presentation at the
EORTC-AACR-NCI Symposium entitled “Synergistic Anti-Tumour Activity of Oncolytic Reovirus and
Docetaxel in a PC-3 Prostate Cancer Mouse Model” at the EORTC-AACR-NCI Symposium on Molecular
Targets and Cancer Therapeutics being held in Geneva, Switzerland, from October 21-24, 2008.
Dr. Shizuko Sei et al is scheduled to deliver a poster presentation entitled “In Vivo Efficacy and
Replication Dynamics of Intravenously Administered Oncolytic Reovirus in Nude Mice Bearing Human
Melanoma Xenografts” at the EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the materials presented at these meetings with respect to REOLYSIN®, the
Company’s expectations related to the results of trials investigating delivery of
REOLYSIN®,
and the Company’s belief as to the potential of REOLYSIN® as a
cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the
Company’s actual results to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of
REOLYSIN® as a cancer treatment, the
success and timely completion of clinical studies and trials, the Company’s ability to successfully
commercialize REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company’s quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking
statements, except as required by applicable laws.
FOR FURTHER INFORMATION PLEASE CONTACT:
| |
|
|
|
|
Oncolytics Biotech Inc.
Cathy Ward
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
Tel: 403.670.7377
Fax: 403.283.0858
cathy.ward@oncolytics.ca
|
|
The Equicom Group
Nick Hurst
325, 300 5th Ave. SW
Calgary, Alberta T2P 3C4
Tel: 403.538.4845
Fax: 403.237.6916
nhurst@equicomgroup.com
|
|
The Investor Relations Group
Erika Moran
11 Stone St, 3rd Floor
New York, NY 10004
Tel: 212.825.3210
Fax: 212.825.3229
emoran@investorrelationsgroup.com |
-30-